Clinical Trial

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-09-15; most recent amendment 2026-03-05.
Status change: Recruiting → Active, Not Recruiting 2026-02-12
Status change: Not Yet Recruiting → Recruiting 2023-10-06
Trial Details
NCT Number NCT06049134
Lead Sponsor M.D. Anderson Cancer Center
Conditions Lymphoma
Enrollment 30 participants
Start Date 2023-10-06
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-09